1. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.

2. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012; 14(1): 1-10.

3. Roe MT, Ou FS, Alexander KP et al. Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST – segment elevation acute coronary syndromes. Eur Heart J 2008; 20: 2480-2488.

4. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovascular Risk 1996; 2: 213-219.

5. Belsey J, de Lusignan S, Chan T et al. Abnormal lipids in high-risk patients achieving cholesterol targets: a cross-sectional study of routinely collected UK general practice data. Curr Med Res Opin 2008; 9: 2551-2560.

6. Fruchart JC, Sachs FM, Hermans MP et al. The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in dyslipidemic patients. Am J Cardiol 2008; 102(suppl 10A): 1K-34K.

7. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 2008; 14(8 Suppl): S3-28.

8. Jenkins AJ, Rowley KG, Lyons TJ et al. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004; 10: 3395-3418.

9. Davis DD, Fisher MR, Gangnon RE et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998; 39: 233-252.

10. Lyons TJ, Jenkins AJ, Zheng D et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-918.

11. Smulders YM, Rakic M, Stehouwer CDA et al. Determinants of progression of microalbuminuria in patients with NIDDM. A prospective study. Diabetes Care 1997; 20: 999-1005.

12. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000; 49: 1399-1408.

13. Retnakaran R, Cull CA, Thorne KI et al.; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-1839.

14. Colhoun HM, Betteridge DJ, Durrington PN et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo controlled trial. Lancet 2004; 364: 685-696.

15. Kempler P, Tesfaye S, Chaturvedi N et al.; EURODIAB IDDM Complications Study Group. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med 2002; 19: 900-909.

16. Baigent C, Keech A, Kearney PM et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-1278.

17. LaRosa JC, Grundy SM, Waters DD et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.

18. Miller M, Cannon CP, Murphy SA et al.; PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008; 51: 724-730.

19. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 Suppl A: A2-11.

20. Barter P, Gotto AM, LaRosa JC et al.; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.

21. Ali YS, Linton MF, Fazio S. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. Curr Opin Endocrinol Diabetes Obes 2008; 15(2): 142-146.

22. ACCORD Study Group. Buse JB, Bigger JT, Byington RP et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007; 99 (12A): 21i-33i.

23. Ginsberg HN, Elam MB, Lovato LC et al.; ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med 2010; 362(17): 1563-1574.

24. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2015. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabet. Klin. 2015; 4(supl. A): 1-73.

25. Davis M, Fisher M, Gangnon R et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report. Invest Ophtalmol Vis Sci 1998; 39: 233-252.

26. Ansquer JC, Foucher C, Rattier S et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45: 485-493.

27. Keech A, Simes RJ, Barter P et al.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849-1861.

28. Rajamani K, Colman PG, Li LP et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-1788.

29. ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363(3): 233-244.